Boston Scientific_ Reminder why it's the BOS

Summary of Boston Scientific Conference Call Company Overview - Company: Boston Scientific (BSX) - Industry: Medical Technology - Market Cap: $154.214 billion - **Stock Rating**: Overweight - **Price Target**:$100.00 - Current Price (Feb 4, 2025): $103.54 - **52-Week Range**:$104.25 - $64.09 [5][66] Key Financial Highlights - **Q4 Sales**:$4,561 million, 3% above Visible Alpha consensus [3][8] - Cardiovascular Organic Growth: +27.4%, exceeding Street expectations of +22% [3][8] - MedSurg Revenue Growth: +7.0%, in line with expectations [3][8] - Cardiology Performance: +32% organic growth, driven by FARAPULSE and WATCHMAN [3][8] - Neuromodulation Growth: +5.5% organic growth, a notable acceleration from previous quarters [3][8] - 2025 Guidance: Expected organic growth of +10-12%, significantly higher than prior expectations of +9-10% [2][7] Investment Thesis - Strong Q4 Performance: The results reinforce the investment thesis, showcasing Boston Scientific's robust growth potential and pipeline [2][7]. - Acquisitions Impact: Recent acquisitions (Axonics, Silk, Relievant) are expected to contribute positively to organic growth in 2026, which may be underestimated by the market [2][7]. - Earnings Per Share (EPS) Guidance: 2025 EPS guidance of $2.80 -$2.87 suggests a clear pathway to $3.00, aligning with bullish expectations [2][7]. Market Position and Competitive Landscape - Competitive Positioning: The company is well-positioned in the MedTech sector, with a strong pipeline and growth potential that is not easily matched by competitors [2][7]. - Focus on Key Products: The narrative around FARAPULSE and WATCHMAN is strong, but the overall performance across divisions indicates a broader strength [2][7]. Risks and Considerations - Market Underestimation: There is a risk that the market may underestimate the organic impact of recent acquisitions and the overall growth potential of Boston Scientific [7][12]. - Competitive Pressures: Increased competition in core markets could pose challenges, particularly in the drug-eluting stent (DES) and cardiac rhythm management (CRM) sectors [12]. Conclusion - Boston Scientific's recent performance and guidance indicate a strong outlook for 2025, supported by robust growth across multiple divisions and strategic acquisitions. The company remains a compelling investment opportunity within the medical technology sector, with a favorable risk-reward profile.